Francisco Silva - 17 Feb 2023 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director, 10%+ Owner
Signature
/s/ Francisco Silva
Issuer symbol
BRTX
Transactions as of
17 Feb 2023
Net transactions value
$0
Form type
4
Filing time
17 Feb 2023, 16:29:34 UTC
Previous filing
21 Nov 2022
Next filing
28 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BRTX Common Stock 166,046 17 Feb 2023 Direct F1
holding BRTX Common Stock 12,136 17 Feb 2023 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRTX Stock Option Award $0 +106,762 $0.000000 106,762 17 Feb 2023 Common Stock 106,762 $2.91 Direct F5
holding BRTX Stock Option 1 17 Feb 2023 Common Stock 1 $3000.00 Direct F2
holding BRTX Stock Option 3 17 Feb 2023 Common Stock 3 $3000.00 Direct F2
holding BRTX Stock Option 1 17 Feb 2023 Common Stock 1 $3000.00 Direct
holding BRTX Stock Option 9 17 Feb 2023 Common Stock 9 $3000.00 Direct F2
holding BRTX Stock Option 6 17 Feb 2023 Common Stock 6 $3000.00 Direct F2
holding BRTX Stock Option 15 17 Feb 2023 Common Stock 15 $3000.00 Direct F2
holding BRTX Stock Option 20 17 Feb 2023 Common Stock 20 $3000.00 Direct F2
holding BRTX Stock Option 25 17 Feb 2023 Common Stock 25 $3000.00 Direct F2
holding BRTX Stock Option 293,479 17 Feb 2023 Common Stock 293,479 $5.08 Direct F3
holding BRTX Stock Option 42,059 17 Feb 2023 Common Stock 42,059 $5.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F2 The option is currently exercisable.
F3 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F4 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.
F5 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 with the remaining 53,381 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.